FibroGen, Inc.

104 articles with FibroGen, Inc.

• 

  The 20 Hottest Pipeline Drugs to Watch in 2019

  1/3/2019

  EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
• 

  AstraZeneca on a Roll: Positive Data in Three Clinical Trials for Two Different Drugs

  12/20/2018

  AstraZeneca released data from two clinical trials of roxadustat in anemia and of its trial of Lynparza in ovarian cancer. All the trials had positive results.

• FIBROGEN APPOINTS MAYKIN HO, PH.D., TO BOARD OF DIRECTORS

  12/6/2018

  FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced the appointment of Maykin Ho, Ph.D., as an independent director to FibroGen’s Board of Directors. 

• 

  AstraZeneca's Danilo Verge on Company's Cardiovascular, Renal and Metabolic Approach -- Interview

  10/26/2018

  AstraZeneca is presenting literally dozens of abstracts at this week’s American Society of Nephrology Kidney Week Annual Meeting in San Diego. Not only does it represent ongoing research on already approved drugs, but promising pipeline products. 
• 

  Astellas Pushes Outside of Oncology, Releases Positive Results in Anemia Trials

  9/21/2018

  Tokyo-based Astellas Pharma announced that its roxadustat met its primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease (CKD) patients with anemia not on dialysis. The focus of the drug is on anemia.

• FibroGen Reports Third Quarter 2017 Financial Results

  11/9/2017

  FibroGen will host a conference call and webcast today, November 8, 2017, at 5:00 p.m. ET to discuss financial results and provide a business update.

• FibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017

  10/31/2017

  The company will host a conference call to discuss financial results and provide a business update at 5:00 p.m. ET (2:00 p.m. PT).

• Week in Review: WuXi AppTec Acquires US-Global Clinical CRO

  10/23/2017

  WuXi AppTec, a China CRO/CMO, will acquire ResearchPoint Global, of Texas, a global clinical-stage contract research company, to extend the reach of its own clinical CRO coverage.

• FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD)

  10/18/2017

  The NDA submission triggers a $15 million milestone payment, payable to FibroGen by AstraZeneca.

• FibroGen Appoints Gerald Lema To Board Of Directors

  9/20/2017

• FibroGen Presents Latest Data From Phase IIb Study Of Pamrevlumab In Idiopathic Pulmonary Fibrosis At European Respiratory Society (ERS) International Congress 2017

  9/13/2017

• FibroGen Announces Pricing Of Follow-On Offering Of Common Stock

  8/16/2017

• FibroGen Announces Proposed Follow-On Offering Of Common Stock

  8/15/2017

• FibroGen Reports Second Quarter 2017 Financial Results

  8/8/2017

• FibroGen Announces Positive Topline Results From Phase II Study Of Pamrevlumab In Idiopathic Pulmonary Fibrosis

  8/8/2017

• FibroGen To Report Second Quarter Financial Results On Monday, August 7, 2017

  8/1/2017

• FibroGen Granted Orphan Drug Designation For Pamrevlumab In The Treatment Of Pancreatic Cancer

  6/22/2017

• European Patent Office Maintains FibroGen Patent Relating To Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology

  6/5/2017

• FibroGen Reports First Quarter 2017 Financial Results

  5/10/2017

• FibroGen's Novel Anemia Treatment Meets Phase III Endpoints In China

  1/31/2017